

Open access

614 Views | 17 CrossRef citations to date | 0 Altmetric

Listen

Article Addendum

# The role of M3-muscarinic receptor signaling in insulin secretion

Kok Choi Kong & Andrew B. Tobin

Pages 489-491 | Received 04 Apr 2011, Accepted 04 Apr 2011, Published online: 01 Jul 2011

Cite this article <https://doi.org/10.4161/cib.15716>

Full Article

Figures & data

References

Citations

Metrics

Licensing

Reprints & Permissions

View PDF

Share

## We Care About Your Privacy

We and our 880 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting I Accept enables tracking technologies to support the purposes shown under we and our partners process data to provide. Selecting Reject All or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Show Purposes link on the bottom of the webpage. Your choices will have effect within our Website. For more details, refer to our Privacy Policy. [Here](#)

We and our partners process data to provide:

Use precise geolocation data. Actively scan device

I Accept

Reject All

Show Purpose

Insulin secretion by  $\beta$  cells of the islets of Langerhans in the pancreas is a process tightly regulated by glucose and other circulating nutrients. It is also modulated by many other factors, including hormones and neurotransmitters. One of the most prominent of these regulatory mechanisms is mediated by acetylcholine (ACh) originating from the parasympathetic cholinergic input.<sup>1,2</sup> Although cholinergic regulation of insulin release has been known for many years, the mechanism of regulation and in particular the identity of the subtype of cholinergic receptor responsible for this regulation has only recently been established. There are five cholinergic muscarinic receptor subtypes ( $M_1$ – $M_5$ ) and the work of Gautam and colleagues using transgenic and gene knockout technology have determined that the  $M_3$ -muscarinic receptor ( $M_3R$ ) is the bona fide acetylcholine receptor that is responsible for enhancing glucose-dependent insulin release in  $\beta$  cells.<sup>3</sup>

## Molecular Mechanisms for $M_3R$ -Mediated Insulin Secretion

The mechanism by which  $M_3R$  regulates insulin release was thought to be primarily via G-protein depending signaling to the calcium and PKC pathways. As a prototypical

$G_{q/11}$ -coupled receptor,  $M_3R$  activates phospholipase C (PLC). The activation of PLC leads to the production of diacylglycerol (DAG) and inositol trisphosphate ( $IP_3$ ) and these molecules play an important role in  $M_3R$  mediated insulin release.

How  $M_3R$  mediates insulin release is not clear. In particular, it appears to be mediated by a protein-kinase dependent mechanism. In fact, studies have shown that  $M_3R$  activates protein-kinase D1 (PKD1) and this is dependent on the production of DAG.  $M_3R$  via a G-protein dependent mechanism activates vesicle priming and insulin release by



inhibiting the mitogen activated protein kinase p38 $\delta$  activity, which has inhibitory effects on PKD1 in  $\beta$  cells.[5](#)

Other studies have, however, returned to the importance of calcium signaling. Healy and colleagues demonstrated that the expression level of IP<sub>3</sub>-receptors in  $\beta$  cells is crucial for M3R-mediated insulin release.[6](#) Binding of the adaptor protein ankyrin-B to the IP<sub>3</sub>-receptors in  $\beta$  cells stabilizes the receptors and thus enhances the calcium signal in the cells.[6](#) Pancreatic islets from heterozygous ankyrin-B mutant (ankB<sup>+/-</sup>) mice exhibited a reduction in both basal and carbachol-stimulated intracellular calcium release,[6](#) suggesting that the IP<sub>3</sub>-receptor is stabilized in the open state.

In addition, the sodium channel designated NALCN, which is short for sodium leak channel non-selective, has also been demonstrated to play a role in M3R-mediated insulin release.[7](#) This channel, formerly named Rb21 then VGICL1, belongs to the four domain ion channel family. M3R has been shown to activate this channel in the model pancreatic  $\beta$  cell line, MIN-6, via the Src family of tyrosine kinases (SFKs).[7](#) In addition, one more piece of the jigsaw puzzle is the regulators of G-protein signaling protein, RGS4. Ruiz de Azua and colleagues have demonstrated that RGS4 negatively modulate M3R-mediated insulin secretion in  $\beta$  cells due to its selective inhibition of M3R signaling in  $\beta$  cells.[8](#)

Hence, there appears to be a number of possible *in vivo* mechanisms that act in concert



(Fig. 1).

Physio

on

Though

have only

recently

s in

regu

ver a decade

ago.[9](#) An

receptor

agonists

glucose-

stimulat

et, but also

normaliz

ice

subjecte

oment of

islet-spe

ight be a



This proposal has only been put to vigorous investigation in recent years. After identifying M3R as the bona fide acetylcholine receptor that is responsible for enhancing glucose-dependent insulin release, Gautam and colleagues performed a series of studies which concluded with the generation of transgenic mice that express a constitutively active mutant of M3R specifically in pancreatic  $\beta$  cells in order to mimic the effects of a drug that chronically activates  $\beta$  cell M3Rs.<sup>10</sup> These mutant mice exhibited markedly improved glucose tolerance and increased serum insulin levels as well as resistance to diet-induced glucose intolerance and hyperglycemia.<sup>10</sup> These studies strongly supported the hypothesis that chronic, sustained activation of  $\beta$  cell M3Rs might produce beneficial effects to glucose homeostasis, and further established the therapeutic potential for M3R selective agonists for the treatment of type II diabetes. However, due to the multiple peripheral actions of M3Rs such as smooth muscle contraction and saliva secretion, the use of such agonists may be limited by their possible side effects.

## Clinical Targeting of M3R Signaling in Insulin Secretion in Disease

The notion of targeting M3Rs in disorders where insulin secretion is de-regulated such as type II diabetes runs into the difficulty of developing ligands that are selective to the M3R subtypes, namely  $M_{3A}$  and  $M_{3B}$ , or subtypes, namely  $M_{3A}$  and  $M_{3B}$ . Muscarinic receptors are found throughout the body and are involved in a wide range of physiological processes. The hope for selective M3R agonists is that they can be used with the same efficacy as the non-selective agonists. These so-called allosteric modulators are thought to be able to modulate the activity of the receptor without acting as a full agonist or antagonist. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be designed to be more selective for one subtype of the receptor than another. In addition, these allosteric modulators can be demonstrated



The therapeutic efficacy of carvedilol in the treatment of heart disease has been attributable to the fact that this ligand can direct signaling of the  $\beta$ -adrenoceptor to the arrestin-dependent pathways.<sup>13</sup> Similar biased ligands that direct signaling of the M3R via arrestin signaling would be expected to potentiate insulin release at  $\beta$ -islets in a manner that results in reduced side effects since G-protein-dependent calcium signaling would be minimized.

It is also possible to target the signaling proteins downstream of M3Rs. In particular, PKD1 and ankyrin-B are two potentially promising targets as evidenced by both in vitro and in vivo data. Though homozygous PKD1-knockout (PKD1<sup>-/-</sup>) mice are embryonic lethal,<sup>14</sup> deletion of PKD1 in INS1 insulinoma cells completely abolished the insulin release induced by glucose and carbachol.<sup>5</sup> siRNA-knockdown of PKD1 in mouse islets also impaired the M3R-mediated augmentation of glucose-induced insulin secretion.<sup>4</sup> Carbachol augmentation of glucose-induced insulin secretion was significantly impaired in islets prepared from ankB<sup>+/-</sup> mice or in rat islets following siRNA-knockdown of ankyrin-B.<sup>6</sup> In addition, ankB<sup>+/-</sup> mice exhibited hyperglycemia after oral ingestion of glucose and the R1788W mutation of ankyrin-B impaired its function in islets and is associated with type II diabetes in Caucasians and Hispanics.<sup>6</sup> These studies demonstrate that targeting the signaling pathways downstream of the M3R can effectively modulate insulin release.

## Conclu



It is now  
treatment  
insulin s

The r  
down  
and in p  
conduct

## Figure



Figure 1 The possible mechanisms of M<sub>3</sub>-muscarinic receptor (M3R)-mediated insulin secretion. Conventional studies have provided evidence that the transient, early phase of insulin secretion is mediated by M3R via G protein-dependent signaling that results in increase in intracellular calcium and activation of protein kinase C.<sup>1</sup> Recent studies have shown that the sustained, late phase of insulin secretion is enhanced by M3R via G protein-independent pathways which requires receptor phosphorylation/arrestin-dependent signaling to PKD1<sup>4</sup> and Src family tyrosine kinases signaling to sodium channel NALCN.<sup>7</sup>



Trans  
G p  
Display fu  
Addendu  
Refer  
1. Gilon  
contro

olinerpic

2. Malaisse WJ. Stimulus-secretion coupling in the pancreatic B-cell: the cholinergic pathway for insulin release. *Diabetes Metab Rev* 1986; 2:243 - 259

 | [PubMed](#) | [Google Scholar](#)

3. Gautam D, Han SJ, Hamdan FF, Jeon J, Li B, Li JH, et al. A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. *Cell Metab* 2006; 3:449 - 461

 | [PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

4. Kong KC, Butcher AJ, McWilliams P, Jones D, Wess J, Hamdan FF, et al. M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1. *Proc Natl Acad Sci USA* 2010; 107:21181 - 21186

 | [PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

5. Sumara G, Formentini I, Collins S, Sumara I, Windak R, Bodenmiller B, et al. Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis. *Cell* 2009; 136:235 - 248

 | [PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

6. Healy JA, Nilsson KR, Hohmeier HE, Berglund I, Davis I, Hoffman I, et al. Cholinergic augm




7. Swayr... The NALCN  
ion ch... cell line.  
EMBO

[Google](#)



8. Ruiz... t al. RGS4 is  
a nega... and in vivo.  
Proc N

9. Ahren... lization of

0. Gautam D, Ruiz de Azua I, Li JH, Guettier JM, Heard T, Cui Y, et al. Beneficial metabolic effects caused by persistent activation of beta-cell M3 muscarinic acetylcholine receptors in transgenic mice. *Endocrinology* 2010; 151:5185 - 5194  
 | [PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)
1. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. *Nat Rev Drug Discov* 2009; 8:41 - 54  
 | [PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)
2. May LT, Leach K, Sexton PM, Christopoulos A. Allosteric modulation of G protein-coupled receptors. *Annu Rev Pharmacol Toxicol* 2007; 47:1 - 51  
 | [PubMed](#) | [Google Scholar](#)
3. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. *Proc Natl Acad Sci USA* 2007; 104:16657 - 16662  
 | [PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

4. Fielitz  | [PubMed](#) | [Web of Science ®](#) | [Google Scholar](#) | [Full text of protein kinase](#) 2008; 105:3

Down



Related



## Information for

- Authors
- R&D professionals
- Editors
- Librarians
- Societies

## Opportunities

- Reprints and e-prints
- Advertising solutions
- Accelerated publication
- Corporate access solutions

## Keep up to date

Register to receive personalised research and resources by email

 Sign me up



## Open access

- Overview
  - Open journals
  - Open Select
  - Dove Medical Press
  - F1000Research
- ## Help and information
- Help and contact
  - Newsroom
  - All journals
  - Books

Copyright

Accessib

Registered  
5 Howick Pl

or & Francis Group  
orma business

